Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)
3 Months Ended 9 Months Ended
Oct. 13, 2022
Feb. 10, 2022
Oct. 09, 2017
Sep. 30, 2022
Sep. 30, 2022
Shareholders' Equity (Details) [Line Items]          
Common Stock Issuances, description   On February 10, 2022, the Company, entered into a securities purchase agreement with an accredited institutional investor (“the Investor”) providing for the issuance of (i) 2,322,250 shares of the Company’s common stock, par value $0.001, (ii) pre-funded warrants to purchase up to 1,865,000 shares of common stock with an exercise price of $0.001 per share, which Pre-Funded Warrants are to be issued in lieu of shares of common stock to ensure that the Investor does not exceed certain beneficial ownership limitations, and (iii) warrants, with a term of five years and six months from the date of issuance, to purchase an aggregate of up to 3,977,888 shares of common stock at an exercise price of $2.52 per share.      
Net proceeds from the offering (in Dollars)   $ 9,123,741      
Exercised for proceeds (in Dollars)   $ 1,865      
Common stock available for issuance   1,865,000      
Shares issued       470,000  
Cost of common stock (in Dollars)         $ 818,350
Employee vesting shares, description         During the nine months ended September 30, 2022, the Company issued employees 1,250,000 shares of common stock as bonuses. The first issuance of 250,000 shares are subject to forfeiture for nominal consideration to Company on termination of the employee, the shares no longer being liable to forfeiture (“vesting”) on the following schedule: 1/24 of 166,667 shares vesting on the date of issue and the first of each of the next twenty-three subsequent months, and 83,333 shares vesting on the third anniversary of the date of issue. The second issuance of 1,000,000 shares are subject to forfeiture on the same conditions, but on the following schedule: 1/6 of the issued shares vesting six months from date of issue, then 1/12 vesting at the end of each subsequent three month period, the entire grant being vested three years from date of issue. On September 30, 2022, 55,556 shares were vested and 1,194,444 shares remained subject to repurchase. 
Outstanding options intrinsic value (in Dollars)       $ 0 $ 0
Options to purchase shares of common stock         731,667
Weighted average fair value (in Dollars)         $ 1,017,095
weighted average fair value per share (in Dollars per share)         $ 1.39
Weighted average remaining vesting period         1 year 9 months 18 days
Unrecognized compensation expense (in Dollars)         $ 2,374,688
2017 Equity Incentive Plan [Member]          
Shareholders' Equity (Details) [Line Items]          
Common shares issued 9,500,000   1,750,000   2,414,993
Stock Options [Member]          
Shareholders' Equity (Details) [Line Items]          
Common stock available for issuance       139,686 139,686
Common stock, shares outstanding       4,177,291 4,177,291
Shares issued         2,907,716
Weighted average remaining vesting period         2 years 10 months 20 days
Consultant [Member]          
Shareholders' Equity (Details) [Line Items]          
Fair value of assumptions, description         This table includes warrants to purchase 344,851 shares of common stock issued to consultants, including the 200,000 issued during the nine months ended September 30, 2022, with a total fair value of $263,195 at time of issue, calculated using the Black Scholes model assuming an underlying security values of $2.06, volatility rate of 107.88% risk-free rate of 1.71%, and an expected term of 6.5 years. During the nine months ended September 30, 2022, the Company recognized $305,230 in expense associated with these warrants with no additional expense remaining to be recognized.